Elimination of malignant clonogenic cells from human bone marrow using multiple myeloid cell-specific monoclonal antibodies and complement.
Single or combined monoclonal antibodies (McAbs) Zh53, Zh820, and Zh2-1 have been used to eliminate malignant clonogenic cells from human bone marrow. The test of cytotoxicity showed that all of these McAbs could express high specific cytotoxic action against HL-60 cells and were selectively complement-dependent cytotoxic to various types of fresh leukemic cells. Clonogenic assay detected that single treatment with antibody and rabbit complement (RC) could reduce clonogenic units of HL-60 cells by more than 2 logs and two treatments reduced clonogenic units by more than 4 logs. However, combination of 2 McAbs could reduce clonogenic units by 4-5 logs. The data suggest that multiple treatments with McAbs and RC or a combination of 2 McAbs are more effective than a single treatment in eliminating clonogenic tumor cells. Treatment of normal human bone marrow with Zh53, Zh2-1 and RC did not produce a loss of normal CFU-GM, but treatment with Zh820 reduced the clonic units of normal CFU-GM by 24%.
Institute of Hematology, First Affiliated Hospital, Zhejiang Medical University, Hangzhou.
Z B
ZB
Hu
Z F
ZF
Yu
C N
CN
Qiao
W L
WL
Ma
D000818:Animals; D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm / Q000276:immunology; D001853:Bone Marrow / Q000473:pathology; D003114:Colony-Forming Units Assay; D003165:Complement System Proteins / Q000276:immunology*; D006801:Humans; D007951:Leukemia, Myeloid / Q000276:immunology / Q000473:pathology*; D015473:Leukemia, Promyelocytic, Acute / Q000276:immunology / Q000473:pathology*; D051379:Mice; D011817:Rabbits; D014407:Tumor Cells, Cultured; D014410:Tumor Stem Cell Assay
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D003165:Complement System Proteins